Jean Bennett
Director/Board Member bei REGENXBIO INC.
Vermögen: 63 421 $ am 31.03.2024
Profil
Jean Bennett is the founder of Opus Genetics, Inc. where she holds the title of Director in 2021.
She is also the founder of Spark Therapeutics, Inc., Limelight Bio, Inc., and Gensight Biologics, Inc. Currently, she holds the position of Independent Director at REGENXBIO, Inc. since 2021 and is a Professor-Emeritus at Perelman School of Medicine.
Previously, she was the Director at the Center for Advanced Retinal & Ocular Therapies.
Dr. Bennett received her doctorate degree from Harvard University and the University of California, Berkeley, and her undergraduate degree from Yale University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
REGENXBIO, INC.
0,01% | 01.04.2024 | 3 010 ( 0,01% ) | 63 421 $ | 31.03.2024 |
Aktive Positionen von Jean Bennett
| Unternehmen | Position | Beginn |
|---|---|---|
| REGENXBIO INC. | Director/Board Member | 01.03.2021 |
Opus Genetics, Inc.
 Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Founder | 01.02.2021 |
| Perelman School of Medicine | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Jean Bennett
| Unternehmen | Position | Ende |
|---|---|---|
Limelight Bio, Inc.
 Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Founder | - |
| SPARK THERAPEUTICS, INC. | Founder | - |
| Gensight Biologics, Inc. | Founder | - |
| Center For Advanced Retinal & Ocular Therapies | Director/Board Member | - |
Ausbildung von Jean Bennett
| Harvard University | Doctorate Degree |
| Yale University | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| REGENXBIO INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Limelight Bio, Inc. engages in the development of proprietary technologies, advanced targets, and drug candidates for the expansion of current gene therapy and gene editing approaches. The company was founded by Phil Johnson and Jean Bennett in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
| Gensight Biologics, Inc. | |
| Center For Advanced Retinal & Ocular Therapies | |
Opus Genetics, Inc.
Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Health Technology |
